Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon

被引:10
作者
Kamata, Yasuyuki [1 ]
Minota, Seiji [1 ]
机构
[1] Jichi Med Univ, Div Rheumatol & Clin Immunol, Shimotsuke, Tochigi 3290498, Japan
关键词
Connective tissue diseases; Raynaud's phenomenon; Sildenafil; Tadalafil; Vardenafil; SILDENAFIL; THERAPY; DISEASE;
D O I
10.1007/s00296-014-3025-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Raynaud's phenomenon (RP) is commonly observed in fingers and toes of patients with connective tissue diseases (CTDs). However, existing vasodilators have very limited efficacy. In this study, phosphodiesterase type 5 inhibitors (PDE-5Is) were administered to evaluate efficacy on RP. Three patients with mixed connective tissue disease and three patients with systemic sclerosis having RP were enrolled. Oral sildenafil, vardenafil, or tadalafil was administered. The fingertip temperature was measured by thermography before and 120 min after administration. To evaluate longer effects, vardenafil was administered daily for 12 weeks; the fingertip temperature was measured by thermography before and 12 weeks after administration. As compared with the pre-administration of sildenafil, vardenafil, and tadalafil, the mean fingertip temperature increased by 2.17, 3.47, and 3.59 A degrees C, respectively, in 120 min. In the 12-week trial with vardenafil in 3 patients, the mean fingertip temperature increased by 3.04, 7.96, and 3.32 A degrees C from baseline in each patient. PDE-5Is significantly increased fingertip temperature within 120 min, and the effect of vardenafil lasted for 12 weeks under daily use. PDE-5Is were safe and would be an effective treatment for RP with CTDs.
引用
收藏
页码:1623 / 1626
页数:4
相关论文
共 50 条
[41]   Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis [J].
Abbasi, Behzad ;
Shaw, Nathan M. ;
Lui, Jason L. ;
Hakam, Nizar ;
Nabavizadeh, Behnam ;
Breyer, Benjamin N. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
[42]   Modalités de prescription des inhibiteurs de la phospodiestérase de type 5Phosphodiesterase type 5 inhibitors: modalities of prescription [J].
Dominique Delavierre .
Andrologie, 2004, 14 (2) :239-241
[43]   Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors [J].
Abeles, Aryeh M. ;
Nicolescu, Mirela ;
Pinchover, Zachary ;
Abeles, Micha .
VASCULAR, 2014, 22 (04) :313-316
[44]   Proton pump inhibitors and Raynaud's phenomenon: is there a link? [J].
Khouri, Charles ;
Revol, Bruno ;
Cracowski, Jean-Luc ;
Roustit, Matthieu .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (10) :2443-2444
[45]   Inhaled phosphodiesterase type 5 inhibitors for cystic fibrosis: a new therapy for systemic disease? [J].
Antoniu, Sabina Antonela .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (05) :713-715
[46]   Phosphodiesterase Type 5 Inhibitors Greatly Affect Physicochemical Properties of Model Lipid Membranes [J].
Zakharova, Anastasiia A. ;
Efimova, Svetlana S. ;
Ostroumova, Olga S. .
MEMBRANES, 2021, 11 (11)
[47]   From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity [J].
Abdel-Halim, Mohammad ;
Sigler, Sara ;
Racheed, Nora A. S. ;
Hefnawy, Amr ;
Fathalla, Reem K. ;
Hammam, Mennatallah A. ;
Maher, Ahmed ;
Maxuitenko, Yulia ;
Keeton, Adam B. ;
Hartmann, Rolf W. ;
Engel, Matthias ;
Piazza, Gary A. ;
Abadi, Ashraf H. .
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (08) :4462-4477
[48]   Phosphodiesterase 5 inhibitors in male sexual dysfunction [J].
Kuthe, A .
CURRENT OPINION IN UROLOGY, 2003, 13 (05) :405-410
[49]   Recreational use and misuse of phosphodiesterase 5 inhibitors [J].
Smith, KM ;
Romanelli, F .
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2005, 45 (01) :63-75
[50]   The use of phosphodiesterase 5 inhibitors with concomitant medications [J].
Corona, G. ;
Razzoli, E. ;
Forti, G. ;
Maggi, M. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008, 31 (09) :799-808